Trial Profile

Phase 3 clinical trial of oral insulin (ORMD-0801) in type 2 diabetes in China

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 19 May 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Insulin (Primary)
Indications Diabetes mellitus
Focus Registrational; Therapeutic Use
Sponsors Hefei Tianhui Incubator of Technologies

Most Recent Events

15 May 2023 According to an Oramed Pharmaceuticals media release, the HTIT is now moving toward regulatory approval and has submitted the data to the National Medical Products Administration (NMPA, formerly the CFDA).
15 May 2023 Status changed to completed, according to a Oramed Pharmaceuticals media release.
05 Jul 2019 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com